Results 181 to 190 of about 2,827,577 (391)

Immune response features in children with chronic constipation

open access: yesКубанский научный медицинский вестник, 2016
In the article the results of examination of some immune characteristics, including some autoantibodies in 28 children with chronic constipation are represented. Increased levels of circulating immune complexes and increased spontaneous NST test were the
O. V. Moskalets, V. I. Scherbina
doaj  

Chronic constipation in elderly patients. [PDF]

open access: green, 1993
D J Mack, L Erwin, J D Fulton
openalex   +1 more source

Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder

open access: yesJCPP Advances, EarlyView.
This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical symptoms of autism spectrum disorder (ASD) for children and adolescents. With limited studies available, there is a need for more high‐power studies for the use of Atomoxetine in children and adolescents with autism spectrum disorder.
Nihit Gupta   +3 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

open access: yesThe Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi   +21 more
wiley   +1 more source

MODERN VIEWS ON A PROBLEM OF CONSTIPATION IN CHILDREN — A POSITION OF PEDIATRICIANS

open access: yesПедиатрическая фармакология, 2009
This article highlights the issues of definition and classification of chronic constipation, the most prevailing pathology among gastrointestinal tract diseases.
F.Ch. Shakhtakhtinskaya
doaj   +2 more sources

Evaluation of the efficacy of prucalopride (resolor) in the treatment of patients with chronic constipation

open access: yesТерапевтический архив, 2013
AIM: To evaluate the efficacy of the enterokinetic prucalopride (resolor) in patients with chronic constipation. Subjects. The effect of treatment with prucalopride (resolor) in 109 patients with chronic constipation was analyzed/RESULTS: The effect was ...
M F Osipenko   +4 more
doaj  

Constipation in CKD

open access: yesKidney International Reports, 2020
Constipation is one of the most common gastrointestinal disorders among patients with chronic kidney disease (CKD) partly because of their sedentary lifestyle, low fiber and fluid intake, concomitant medications (e.g., phosphate binders), and multiple ...
Keiichi Sumida   +2 more
doaj  

Limited post-operative narcotic use in elective laparoscopic cholecystectomy [PDF]

open access: yes, 2017
Purpose: To limit narcotics use Cochrane review: multiple studies have shown postoperative pain can be managed with non-narcotic meds with good outcome Less medication related side effects:N/V, constipation, disorientation Prevents substance addiction ...
Josloff, MD, Robert   +3 more
core   +1 more source

Critical mistakes in managing chronic constipation in the older person and how to avoid them: A narrative review

open access: yesJournal of General and Family Medicine, EarlyView.
Abstract Objectives This narrative review identifies pitfalls in managing constipation in older adults and provides evidence‐based recommendations to avoid them. Methods A selective literature search was conducted across electronic databases (PubMed, MEDLINE, Embase, and Cochrane Library) to identify relevant publications on constipation management in ...
Madunil Niriella   +3 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy